Exchange: NYSEMkt·Updated 07:54 PM EST

KAPA News

News
all
press releases
Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Stocktwits
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.
Stocktwits
Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.
Stocktwits

Advertisement|Remove ads.